|
|
| Ovarian and Endometrial Cancers and |
|
| Low-Dose
OCs |
|
|
|
|
|
|
|
|
|
|
|
|
| n | Ovarian cancer |
|||||||||
| n | If protective
effect is due to prevention of |
|||||||||
| “incessant
ovulation,” low-dose OCs are likely |
||||||||||
| protective |
||||||||||
| n | Endometrial
cancer |
|||||||||
| n | Data on
protective effect indicate no significant |
|||||||||
| difference
between 35 µg and >50 µg EE OCs |
||||||||||
|
|
| Cancer and
Steroid Hormone Study/CDC/NICHHD. JAMA. 1987;257:796-800; |
|
| Rosenblatt KA et al. Eur
J Cancer. 1992;28A:1872-1876. |
|
